Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > They know nothing

<< Previous

Bullboard Posts

Next >>

Comment by PinnacleXon Feb 27, 2022 1:28pm

122 Views

Post# 34465801

RE:They know nothing

Trogarzon wrote: I remember this quote by Jim Cramer on CNBC in 2008.... well that’s what we feel like as Th shareholders. The only confort we have is sales guidance for 2022 that they can beat if they are just a bit smart over there. Maybe some big Chinese player can bring some hope to the success factor in Cancer. Paul clearly said in the Q4 call there will be plenty of exit and entry occasions for shareholders in the coming year, whatever that means.

This says it all, what pathetic CEO says this : "there will be plenty of exit and entry occasions for shareholders in the coming year"

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage